Weekly Digest – August 2025 Weekly Digest – August 2025 06 August 2025: Huadong Medicine’s innovative MUC-17 ADC HDM2012 completes dosing of first patient in Phase 1 clinical trial in China Huadong Medicine’s subsidiary, Sino-US Huadong, dosed the first patient […]
Weekly Digest – August 2025 Weekly Digest – August 2025 07 August 2025: Minghui raises $131M ‘pre-IPO’ round to bankroll JAK inhibitor launch, ADC trials Minghui Pharmaceutical raised $131M in a “pre-IPO” round to advance oncology programs, including multiple ADC […]
Weekly Digest – August 2025 Weekly Digest – August 2025 29 July 2025: Alphamab Oncology announces anti-HER2 biparatopic ADC JSKN003 obtained orphan drug designation from the U.S. FDA for the treatment of GC/GEJ Alphamab Oncology’s anti-HER2 biparatopic ADC, JSKN003, received […]
Weekly Digest – August 2025 Weekly Digest – August 2025 28 July 2025: Zymeworks announces FDA clearance of investigational new drug application for ZW251, a novel glypican 3-targeted topoisomerase I inhibitor antibody-drug conjugate Zymeworks received FDA IND clearance for ZW251, […]
Weekly Digest – August 2025 Weekly Digest – August 2025 27 July 2025: Chong Kun Dang’s ADC-based anticancer drug receives FDA approval for Phase 1/2 clinical trials Chong Kun Dang secures FDA nod to launch U.S. Phase 1/2 trials for […]
Weekly Digest – August 2025 Weekly Digest – August 2025 28 July 2025: ESMO 2025, CStone Pharmaceuticals to disclose CS5001 ADC updated study design for the first time The Phase 1 global, multicenter trial of CS5001 is currently ongoing in the U.S., […]
Weekly Digest – August 2025 Weekly Digest – August 2025 27 July 2025: JSKN003 received the U.S FDA approval to initiate a Phase 2 clinical study in the treatment of PROC not restricted by HER2 expression Alphamab Oncology received U.S. […]
Weekly Digest – August 2025 Weekly Digest – August 2025 24 July 2025: Owkin teams up with NeoGenomics and France Tissue Bank to build IHC-dedicated foundation model for AI-driven ADC diagnostics Owkin is developing an AI foundation model trained exclusively […]
Weekly Digest – July 2025 Weekly Digest – July 2025 23 July 2025: Blenrep (Belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma Health Canada approved GSK’s Blenrep in combination with Bortezomib + Dexamethasone or Pomalidomide […]
Weekly Digest – July 2025 Weekly Digest – July 2025 24 July 2025: Mirvetuximab soravtansine approved in UK to treat adult patients who have ovarian, fallopian tube or primary peritoneal cancer The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has […]
